We are live on ! Find out more
SFAM

Springhill Fund Asset Management Portfolio holdings

AUM $20.9M
This Fund
S&P 500
This Quarter Est. Return
+96.95%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$61.6M
AUM Growth
–
Cap. Flow
+$68.8M
Cap. Flow %
111.71%
Top 10 Hldgs %
78.7%
Holding
17
New
17
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$7.9M
2
CYTK icon
Cytokinetics
CYTK
+$6.79M
3
COGT icon
Cogent Biosciences
COGT
+$5.47M
4
AZN icon
AstraZeneca
AZN
+$5.36M
5
VRNA
Verona Pharma
VRNA
+$5.09M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
1
DELISTED
Verona Pharma
VRNA
$6.29M 10.22%
+135,452
New +$5.09M
LEGN icon
2
Legend Biotech
LEGN
$3.65B
$6.21M 10.08%
+190,800
New +$7.9M
CYTK icon
3
Cytokinetics
CYTK
$10.6B
$6.15M 9.99%
+130,735
New +$6.79M
AZN icon
4
AstraZeneca
AZN
$269B
$5.01M 8.14%
+38,250
New +$5.36M
INSM icon
5
Insmed
INSM
$22.4B
$4.8M 7.79%
+69,500
New +$5.01M
VERA icon
6
Vera Therapeutics
VERA
$2.33B
$4.63M 7.51%
+109,400
New +$4.84M
COGT icon
7
Cogent Biosciences
COGT
$6.76B
$4.28M 6.95%
+548,554
New +$5.47M
AKRO
8
DELISTED
Akero Therapeutics
AKRO
$4.21M 6.83%
+151,200
New +$4.58M
MRUS
9
DELISTED
Merus
MRUS
$3.52M 5.72%
+83,800
New +$4.02M
CGEM icon
10
Cullinan Oncology
CGEM
$1.06B
$3.37M 5.47%
+276,400
New +$3.97M
DYN icon
11
Dyne Therapeutics
DYN
$4.68B
$3.09M 5.02%
+131,200
New +$3.88M
NRIX icon
12
Nurix Therapeutics
NRIX
$2.45B
$3.02M 4.91%
+160,500
New +$3.68M
DRUG
13
Bright Minds Biosciences
DRUG
$697M
$2.18M 3.55%
+60,648
New +$2.13M
BCYC
14
Bicycle Therapeutics
BCYC
$269M
$1.63M 2.65%
+116,400
New +$2.49M
JANX icon
15
Janux Therapeutics
JANX
$912M
$1.58M 2.57%
+29,600
New +$1.57M
ABVX
16
Abivax
ABVX
$10.4B
$1.52M 2.47%
+207,600
New +$1.91M
SLNO
17
DELISTED
Soleno Therapeutics
SLNO
$80.6K 0.13%
+1,793
New +$92.9K

Similar funds

FGN
Foundry Group Next Boulder, Colorado $21.1M AUM 35.51% 1-Year Est. Return
NTIMCH
New Thinking Investment Management Company (HK) Hong Kong $20.4M AUM 4.24% 1-Year Est. Return
CJL
Cyrus J. Lawrence New York $26.4M AUM 16.63% 1-Year Est. Return
GDCML
Galaxy Digital Capital Management LP New York $13.5M AUM
TC
Tarsadia Capital New York $5.64M AUM 15.7% 1-Year Est. Return
OWP
Old Well Partners Charlotte, North Carolina $4.55M AUM 27.75% 1-Year Est. Return
MECA
Miller Equity Capital Advisors Irving, Texas $1.45M AUM 7.67% 1-Year Est. Return
SC
Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Springhill Fund Asset Management's Q4 2024 Portfolio in Review

Q4 2024 is the first quarter with a 13F filing on record for Springhill Fund Asset Management, which disclosed 17 positions worth $61.6M. Its ten largest holdings account for 79% of the portfolio.

Its largest position is Legend Biotech: 190,800 shares worth $6.21M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Springhill Fund Asset Management's largest Q4 2024 buy was Legend Biotech: 190,800 shares worth $6.21M.
  • Springhill Fund Asset Management's ten largest holdings make up 79% of its $61.6M portfolio in Q4 2024.
  • Springhill Fund Asset Management disclosed 17 positions in Q4 2024, its first 13F filing on record.

Based on Springhill Fund Asset Management's 13F filing for Q4 2024, filed 13 Feb 2025.